102 related articles for article (PubMed ID: 7488410)
1. Intrapatient comparison of single-agent epirubicin with or without lonidamine in metastatic breast cancer.
Lopez M; Vici P; Di Lauro L; Paoletti G; Gionfra T; Conti F; Carpano S; Pignatti F; Giannarelli D
Eur J Cancer; 1995 Sep; 31A(10):1611-4. PubMed ID: 7488410
[TBL] [Abstract][Full Text] [Related]
2. Cisplatin and epirubicin plus oral lonidamine as first-line treatment for metastatic breast cancer: a phase II study of the Southern Italy Oncology Group (GOIM).
Gebbia V; Borsellino N; Testa A; Latteri MA; Milia V; Valdesi M; Giotta F; Gebbia N; Colucci G
Anticancer Drugs; 1997 Nov; 8(10):943-8. PubMed ID: 9436637
[TBL] [Abstract][Full Text] [Related]
3. Lonidamine significantly increases the activity of epirubicin in patients with advanced breast cancer: results from a multicenter prospective randomized trial.
Dogliotti L; Berruti A; Buniva T; Zola P; Baù MG; Farris A; Sarobba MG; Bottini A; Alquati P; Deltetto F; Gosso P; Monzeglio C; Moro G; Sussio M; Perroni D
J Clin Oncol; 1996 Apr; 14(4):1165-72. PubMed ID: 8648371
[TBL] [Abstract][Full Text] [Related]
4. FEC (5-fluorouracil, epidoxorubicin and cyclophosphamide) versus EM (epidoxorubicin and mitomycin-C) with or without lonidamine as first-line treatment for advanced breast cancer. A multicentric randomised study. Final results.
Pacini P; Rinaldini M; Algeri R; Guarneri A; Tucci E; Barsanti G; Neri B; Bastiani P; Marzano S; Fallai C
Eur J Cancer; 2000 May; 36(8):966-75. PubMed ID: 10885599
[TBL] [Abstract][Full Text] [Related]
5. Time to progression in metastatic breast cancer patients treated with epirubicin is not improved by the addition of either cisplatin or lonidamine: final results of a phase III study with a factorial design.
Berruti A; Bitossi R; Gorzegno G; Bottini A; Alquati P; De Matteis A; Nuzzo F; Giardina G; Danese S; De Lena M; Lorusso V; Farris A; Sarobba MG; DeFabiani E; Bonazzi G; Castiglione F; Bumma C; Moro G; Bruzzi P; Dogliotti L;
J Clin Oncol; 2002 Oct; 20(20):4150-9. PubMed ID: 12377958
[TBL] [Abstract][Full Text] [Related]
6. Clinical modulation of epirubicin resistance by lonidamine in patients with advanced soft-tissue sarcomas.
Lopez M; Carpano S; Dilauro L; Chiatti L; Vici P; Cavaliere F; Gentile P; Citro G
Int J Oncol; 1995 Feb; 6(2):363-7. PubMed ID: 21556546
[TBL] [Abstract][Full Text] [Related]
7. Addition of either lonidamine or granulocyte colony-stimulating factor does not improve survival in early breast cancer patients treated with high-dose epirubicin and cyclophosphamide.
Papaldo P; Lopez M; Cortesi E; Cammilluzzi E; Antimi M; Terzoli E; Lepidini G; Vici P; Barone C; Ferretti G; Di Cosimo S; Nistico C; Carlini P; Conti F; Di Lauro L; Botti C; Vitucci C; Fabi A; Giannarelli D; Marolla P
J Clin Oncol; 2003 Sep; 21(18):3462-8. PubMed ID: 12972521
[TBL] [Abstract][Full Text] [Related]
8. Cisplatin, epirubicin, and vindesine with or without lonidamine in the treatment of inoperable nonsmall cell lung carcinoma: a multicenter randomized clinical trial.
Ianniello GP; De Cataldis G; Comella P; Scarpati MD; Maiorino A; Brancaccio L; Cioffi R; Lombardi A; Carnicelli P; Tinessa V
Cancer; 1996 Jul; 78(1):63-9. PubMed ID: 8646728
[TBL] [Abstract][Full Text] [Related]
9. Cisplatin, epirubicin, and lonidamine combination regimen as first-line chemotherapy for metastatic breast cancer: a pilot study.
Dogliotti L; Danese S; Berruti A; Zola P; Buniva T; Bottini A; Richiardi G; Moro G; Farris A; Baù MG; Porcile G
Cancer Chemother Pharmacol; 1998; 41(4):333-8. PubMed ID: 9488603
[TBL] [Abstract][Full Text] [Related]
10. Randomized phase II study of single-agent epirubicin +/- verapamil in patients with advanced metastatic breast cancer. An AIO clinical trial. Arbeitsgemeinschaft Internistische Onkologie of the German Cancer Society.
Mross K; Bohn C; Edler L; Jonat W; Queisser W; Heidemann E; Goebel M; Hossfeld DK
Ann Oncol; 1993 Jan; 4(1):45-50. PubMed ID: 8435362
[TBL] [Abstract][Full Text] [Related]
11. A phase II study of methotrexate, doxorubicin, cyclophosphamide, and lomustine chemotherapy and lonidamine in advanced non-small cell lung cancer.
Buccheri G; Ferrigno D; Rosso A
Cancer; 1993 Sep; 72(5):1564-72. PubMed ID: 8394198
[TBL] [Abstract][Full Text] [Related]
12. Combination of epirubicin and lonidamine for treatment of advanced breast cancer.
Moraglio L; Brema F; Pastorino G; Martini MC; Vallauri M
Tumori; 1995; 81(2):107-11. PubMed ID: 7778213
[TBL] [Abstract][Full Text] [Related]
13. Weekly epirubicin plus lonidamine in advanced breast carcinoma.
Nisticò C; Garufi C; Milella M; D'Ottavio AM; Vaccaro A; Fabi A; Terzoli E
Breast Cancer Res Treat; 1999 Aug; 56(3):233-7. PubMed ID: 10573114
[TBL] [Abstract][Full Text] [Related]
14. Lonidamine in high-risk breast cancer patients.
Possinger K; Wagner H; Kovacs S; Flath B; Classen S; Wilmanns W
Semin Oncol; 1991 Apr; 18(2 Suppl 4):58-61. PubMed ID: 2031199
[TBL] [Abstract][Full Text] [Related]
15. Phase II study of paclitaxel and epirubicin as first-line therapy in patients with metastatic breast cancer.
Lück HJ; Thomssen C; du Bois A; Untch M; Lisboa B; Köhler G; Diergarten K
Semin Oncol; 1997 Oct; 24(5 Suppl 17):S17-35-S17-39. PubMed ID: 9374090
[TBL] [Abstract][Full Text] [Related]
16. Modulating effect of lonidamine on response to doxorubicin in metastatic breast cancer patients: results from a multicenter prospective randomized trial.
Amadori D; Frassineti GL; De Matteis A; Mustacchi G; Santoro A; Cariello S; Ferrari M; Nascimben O; Nanni O; Lombardi A; Scarpi E; Zoli W
Breast Cancer Res Treat; 1998 Jun; 49(3):209-17. PubMed ID: 9776504
[TBL] [Abstract][Full Text] [Related]
17. Modulation by lonidamine on the combined activity of cisplatin and epidoxorubicin in human breast cancer cells.
Silvestrini R; Gornati D; Zaffaroni N; Bearzatto A; De Marco C
Breast Cancer Res Treat; 1997 Jan; 42(2):103-12. PubMed ID: 9138599
[TBL] [Abstract][Full Text] [Related]
18. Mitomycin-C, vinblastine, and lonidamine as salvage treatment of advanced breast cancer. A pilot study.
Zaniboni A; Montini E; Simoncini E; Marpicati P; Arcangeli G; Meriggi F; Marini G
Am J Clin Oncol; 1990 Dec; 13(6):520-3. PubMed ID: 2122716
[TBL] [Abstract][Full Text] [Related]
19. A randomised trial of MACC chemotherapy with or without lonidamine in advanced non-small cell lung cancer. Cuneo Lung Cancer Study Group (CuLCaSG).
Buccheri G; Ferrigno D
Eur J Cancer; 1994; 30A(10):1424-31. PubMed ID: 7833096
[TBL] [Abstract][Full Text] [Related]
20. A phase II study of high-dose epirubicin (EPI) plus cyclophosphamide (CPA) with G-CSF for breast cancer patients with visceral metastases or hormone-independent tumors: a trial of the Japan Clinical Oncology Group.
Takashima S; Saeki T; Adachi I; Watanabe T; Sasaki Y; Murai H; Tabei T; Ogita M; Sano M; Kanda K; Shimoyama M
Jpn J Clin Oncol; 1997 Oct; 27(5):325-30. PubMed ID: 9390210
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
